Department of Biomaterials, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Ansary Stem Cell Institute, Department of Genetic Medicine, Weill Cornell Medical College, 1300 York Ave., New York, NY 10065, USA.
Adv Drug Deliv Rev. 2014 Jul;74:104-14. doi: 10.1016/j.addr.2013.09.009. Epub 2013 Sep 27.
This review is intended to provide an overview of tissue engineering strategies using scaffold biomaterials to develop a vascularized tissue engineered construct for nano-pathophysiology. Two primary topics are discussed. The first is the biological or synthetic microenvironments that regulate cell behaviors in pathological conditions and tissue regeneration. Second is the use of scaffold biomaterials with angiogenic factors and/or cells to realize vascularized tissue engineered constructs for nano-pathophysiology. These topics are significantly overlapped in terms of three-dimensional (3-D) geometry of cells and blood vessels. Therefore, this review focuses on neovascularization of 3-D scaffold biomaterials induced by angiogenic factors and/or cells. The novel strategy of this approach in nano-pathophysiology is to utilize the vascularized tissue engineered construct as a tissue model to predict the distribution and subsequent therapeutic efficacy of a drug delivery system with different physicochemical and biological properties.
这篇综述旨在提供一个使用支架生物材料来开发用于纳米病理生理学的血管化组织工程构建体的组织工程策略概述。讨论了两个主要主题。第一个是调节病理条件下细胞行为和组织再生的生物或合成微环境。第二个是使用具有血管生成因子和/或细胞的支架生物材料来实现用于纳米病理生理学的血管化组织工程构建体。就细胞和血管的三维(3-D)几何形状而言,这两个主题有很大的重叠。因此,本综述重点关注血管生成因子和/或细胞诱导的 3-D 支架生物材料的新血管生成。这种方法在纳米病理生理学中的新策略是利用血管化组织工程构建体作为组织模型,预测具有不同物理化学和生物学特性的药物输送系统的分布和随后的治疗效果。